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Alimentary mucositis is a major dose-limiting toxicity associated with anticancer treatment. It is responsible for reducing patient
quality of life and represents a signiﬁcant economic burden in oncology. The pathobiology of alimentary mucositis is extremely
complex, and an increased understanding of mechanisms and pathway interactions is required to rationally design improved
therapies. This review describes the latest advances in deﬁning mechanisms of alimentary mucositis pathobiology in the context
of pathway activation. It focuses particularly on the recent genome-wide analyses of regimen-related mucosal injury and the
identiﬁcation of speciﬁc regulatory pathways implicated in mucositis development. This review also discusses the currently known
alimentary mucositis risk factors and the development of novel treatments. Suggestions for future research directions have been
raised.
Copyright © 2008 J. M. Bowen and D. M. K. Keefe. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.Introduction
Recent research has indicated that cytotoxic chemotherapy
causes unwanted normal tissue damage via its eﬀects on a
multitudeofcellularregulatorypathways[1,2].Inparticular,
investigations have begun to elucidate the role of regula-
tory pathway activation and suppression in regimen-related
gastrointestinal toxicity [2, 3]. Mucosal toxicity following
anticancer treatment is clinically referred to as mucositis.
Mucositis was once separated into oral and gastrointestinal,
however it is now widely known as alimentary mucositis,
referring to the damage which occurs along the entire
orodigestive tract. Alimentary mucositis aﬀects the mucosa,
causing mouth and throat pain, ulceration, abdominal pain,
bloating, vomiting, and diarrhoea depending on the target
tissue [4–6]. The general mechanisms underpinning the
development of mucositis are thought to be the same
regardless of the location along the length of the tract.
However, the kinetics of symptom development is diﬀerent
in each region, which is thought to reﬂect the local turnover
rate of epithelial cells and specialised diﬀerentiation for local
function [4, 7]. The frequency of alimentary mucositis varies
depending on the cancer and treatment, ranging from 10–
40%inpatientsundergoingstandardchemotherapyforsolid
tumours, up to 60–100% in those undergoing high dose
conditioning chemotherapy for stem cell transplantation
[5, 8].
2. Burden of Alimentary Mucositis
Alimentary mucositis represents a signiﬁcant clinical and
economicburdenin oncology.Thepresenceofanymucositis
during a cycle of chemotherapy signiﬁcantly increases the
risk of dose reduction, the frequency of infections and
bleeding,andincreasesthelengthandcostofhospitalisation.
Reduction in treatment doses leads to reduced survival [9],
and mucositis is also a risk factor for mortality due to
its association with infection [10]. What is more, severe
mucositis has been shown to be a signiﬁcant risk factor for
inferior overall survival, relapse mortality, and nonrelapse
mortality in speciﬁc settings [11]. Resource utilisation for
patients during episodes of mucositis is also signiﬁcantly
increased, with the need for nutritional adjuncts including
ﬂuidreplacement,liquiddiets,andtotalparenteralnutrition.
Due to the association with infection, antibiotic therapy is2 Journal of Oncology
also more common in patients with mucositis. Combined,
this translates to an incremental cost increase of US$3500
per cycle of standard dose chemotherapy with oral mucositis
[12, 13] and US$6000 with both oral and GI mucositis [14].
While the full burden of mucositis has yet to be deﬁned, a
prospective study is ongoing to determine its true quality of
life and economic impact.
3. CurrentOverviewMucositisPathobiology
Accumulating evidence has strengthened the proposed bio-
logical model of mucositis [15, 16]. It is known as the
multiple mechanism model, as it represents a divergence
from the initial linear view that mucositis was purely a result
of cytotoxic agent-induced damage to basal epithelial cells
[17, 18]. There is indeed interference with epithelial stem
cell turnover and increased apoptosis following anticancer
treatment, however this is but one component of the
pathobiology of alimentary mucositis. Rather, the events
that lead to mucosal injury are multifactorial, complex,
and pan tissue and are driven initially by the submucosa
via endothelial signalling [16, 19]. Epithelial breakdown
represents the clinical stage only and is associated with loss
of barrier integrity, host infection, and considerable pain
[4, 7, 20–22]. Mucositis has been described as having 5
phases, which are overlapping and interactive [16, 22]. The 5
phasesareinitiation,primarydamageresponse/upregulation
andmessagegeneration,signalampliﬁcation,ulceration,and
healing. Brieﬂy, cytotoxic agents initiate damage through
the generation of reactive oxygen species which causes both
direct damage to tissue components of the mucosa and also
activates secondary signalling. The primary event of the
message generation phase centres around activation of the
transcription factor NFkB, which leads to the upregulation
of many genes involved in perpetuating mucosal injury,
including proinﬂammatory cytokines, adhesion molecules,
and cyclooxygenase-2. During the third phase, a feedback
loop occurs whereby the proinﬂammatory cytokine, TNF,
acts on a number of pathways to reinforce NFkB activation
and the ceramide pathway. The ulcerative phase comprises
loss of mucosal integrity and bacterial colonisation, with
subsequent further proinﬂammatory cytokine production.
Alimentarymucositisisusuallyself-resolvingoncetreatment
ceases, and healing occurs with renewal of epithelial prolifer-
ation and diﬀerentiation and reestablishment of the normal
localmicrobialﬂora[16,23,24].Itisevidentthatthiscurrent
model incorporates sequential interaction between all cell
and tissue types of the mucosa and submucosa, as well as
tissue factors, cytokines, and elements of the luminal envi-
ronment [25, 26]. Among others, the pathways implicated in
this model include ceramide signalling, extracellular matrix
turnover, oxidative stress signalling, apoptosis, cytokine
signalling, and cell cycling.
4. Special Considerations for the GIT
Mucositis pathobiology has been extrapolated mainly from
research in the oral setting. However there is rapidly accu-
mulating evidence that supports the theory that mechanisms
are similar along the entire length of the alimentary canal.
In models of mucositis, inﬂammatory mediators, TNF
and NFkB, have been shown to increase along the length
of the gastrointestinal tract corresponding to histological
damage [27, 28]. Furthermore, proinﬂammatory cytokines,
interleukin 1 and 6, are increased following methotrexate
treatment and associated with a loss of gut barrier function
[29]. Disruption of these signalling pathways ameliorates
intestinal mucositis. Treatment with NFkB inhibitors has
been shown to partially prevent mucosal injury in an
animal model of anticancer treatment [30]. Another anti-
inﬂammatory agent under development, RDP58, signiﬁ-
cantly inhibited intestinal damage induced by irinotecan
through its ability to prevent treatment-related increases
in TNF, Interferon-γ, and interleukin-12 [31]. Research is
ongoing to fully elucidate the mechanisms of gastrointestinal
mucositis. Loss of crypt stem cells remains an important
event in intestinal injury following anticancer treatment.
However, it is not the sole contributing factor leading to
overt damage. The inﬂammatory cascade is being realised
as an important pathway in the development of intestinal
mucositis that can be pharmacologically manipulated.
5. Overview of Current Understanding of
Risk Factors for Mucosal Toxicity
Mucosal susceptibility is based on global and tissue-speciﬁc
factors. Global components are associated with treatment
and patient characteristics, while tissue speciﬁc components
are related to epithelial type, the intrinsic endocrine system,
and the local microbial environment [32]. The choice of
drug, the schedule, and dose-intensity of the regimen will
impact on the risk of toxicity [33]. Patient related variables
includegender,ethnicity, andpresenceofcomorbiditiessuch
as diabetes mellitus [32], although the absolute association
is far less clear for these variables compared to treatment.
Cellular and molecular elements that inﬂuence toxicity will
depend on the local tissue environment, in which mucosal
responses to damaging stimuli, whether direct or indirect
through intermediate mediators, are contingent on the
particularlocationofthetissueandepithelialtype,microbial
environment and speciﬁc regional functions [32].
While the interactions between global and tissue speciﬁc
factors impact on mucosal injury, there are also underlying
genetic inﬂuences that profoundly aﬀect toxicity. The genetic
componentforpredispositiontomucositisiswellestablished
[34, 35]. A classic proof of principle example is the ﬁnding
from clinical trials that genetic susceptibility to apoptosis
can impact on the risk of mucositis. Patients with Addison’s
disease, a condition characterised by excess apoptosis, are
17% more likely to develop oral mucositis during anticancer
treatment,andpatientswithPsoriasis,aconditionofreduced
apoptosis especially in skin, are 77% less likely to suﬀer oral
mucositis [15, 16].
Although this is an elegant example, the most widely
accepted evidence for the genetic basis of mucositis risk is
the observation that patients deﬁcient in drug-metabolising
enzymes are at a higher risk of treatment toxicity [32].Journal of Oncology 3
Table 1: Genetically controlled elements that may directly or indi-
rectly inﬂuence alimentary mucositis risk.
Generic Tissue speciﬁc
Drug metabolism, targets and transport Trefoils
Transcription factors Adhesion factors
Proinﬂammatory cytokines Defensins
Mediators Secretins
Susceptibility to apoptosis and rate Diﬀerential response to
CT/RT
Speciﬁc examples of these include deﬁciencies in UDP-
glucuronosyltransferase 1A1 (UGLT), methylenetetrahydro-
folate reductase (MTHFR), thymidylate synthase (TS), and
dihydropyrimidine dehydrogenase (DYDP), during irinote-
can, methotrexate, and 5-FU treatment, respectively [34,
36]. Reduced levels of these proteins can be caused by
hereditable inactivating mutations in the gene promoter
region and result in accumulation and drug prolonged
exposure. Pharmacogenetics seems an attractive solution to
explain all mucotoxicity, however the proportion of patients
withtheseenzymedeﬁcienciesisgreatlylessthanthenumber
of patients that suﬀer toxicity [2, 32]. It has been suggested
that genetic variants of mucositis mediators, rather than
metabolism enzymes, may be associated with the majority
of toxicity. One such mediator is TNF. Recent studies have
shown that TNF gene polymorphisms are associated with
altered risk of toxicity following cancer treatment [37, 38].
Patients that are heterozygous for the TNF-308 promoter
polymorphism have increased TNF production and are at a
signiﬁcantly greater risk of toxicities following myloablative
chemotherapy treatment. Patients had a 17-fold increased
risk of complications following treatment including those
aﬀecting the oral mucosa, skin, and gut, which is a
stronger association than traditional mucositis risk variables
of gender, age, and treatment dose [37]. Although these
initial ﬁndings are encouraging, the complexity of mucositis
means that there is a continuing challenge to discover
more polymorphisms within candidate genes predictive of
regimen-related mucosal damage. These types of studies
provide accumulating evidence to suggest that a number of
genetically controlled elements can determine the response
of the mucosa to cancer treatment, and that these can be
either generic or tissue speciﬁc (Table 1).
Finally, the most recent area of research involved in
deﬁning risk factors for mucositis is toxicity clustering.
Symptom clustering has previously been applied to a range
of nonmalignant diseases, and to cancer symptoms, and
has proven useful for creating diagnostic criteria. However,
in the context of anticancer treatment-related toxicity, it is
in its infancy [39]. The general principle is that a patient
who has alimentary mucositis is likely to have a particular
subset of other toxicities and vice versa. A recent paper
used Bayesian analysis to identify linked toxicities [39]
and Markov networks to deﬁne clusters of toxicities [40]
in colorectal cancer patients following treatment. It found










Figure 1: Relationship of proposed contributors implicated in
development of alimentary mucositis.
implying that each is a risk factor for the other and may
represent a common underlying aetiology [39]. This novel
work has provided the opportunity to gain a new insight
into the relationship of multiple regimen-related toxicities.
Overall,itseemsthatdeﬁningmucosalinjuryriskfactorsisas
complexasthepathobiology.Themajorcomponentsinclude
global, tissue speciﬁc, genetic and clustering factors, and
these are combined with cellular and molecular interactions
between factors which ultimately determine the mucosal
response to chemotherapy treatment (Figure 1).
6.New AlimentaryMucositisPathway Research
The biological events which induce alimentary mucositis
beginalmostimmediatelyfollowingadministrationofradio-
therapy and chemotherapy [21, 41]. Inhibition of these
early molecular events may have a profound impact on
the intensity of mucosal damage and as such represents an
attractive focus for research. Applying genomic proﬁling to
mucositis research to investigate global molecular changes
following treatment is an increasing area of interest that
holds much promise. The ability to simultaneously inves-
tigate thousands of genes and their response to treatment
has enhanced our ability to deﬁne the mechanisms of
damage speciﬁc to each drug and the generic response
of tissue to anticancer treatment. We can now hypoth-
esis that many genes are initially aﬀected by anticancer
treatment which may be either unique to each drug or
common to all drugs. However, these early genes must
activate a smaller subset of downstream genes, involved in
speciﬁc signalling pathways that are vital to propagating
the cascade towards clinically signiﬁcant mucosal dam-
age. What is more, it is likely that a threshold of key
gene activation must be reached before damage becomes
inevitable.
Two recent studies have directed considerable eﬀort
towards investigating the gene expression changes and
pathway activation responsible for alimentary mucositis
development [2, 3]. Firstly, Sonis et al. investigated the
relationship between gene expression, canonical pathways,
and functional networks in peripheral blood monocytes
of patients who developed mucosal injury in response to
chemoradiation [2]. This study combined Bayesian theory
with network analysis to deﬁne the canonical pathways
most relevant to regimen-related toxicity. They prioritised4 Journal of Oncology
Table 2: The top 14 cellular and regulatory pathways deemed to be most relevant to mucosal injury from anticancer therapy.
Rank Chemoradiation (Sonis, et al.) Irinotecan (Bowen, et al.)
1 Toll-like receptor signalling MAPK signalling
2 NF-kB signalling Cell cycle
3 B-cell receptor signalling Complement and coagulation cascades
4 PI3K/AKT signalling Gap junction
5 Cell cycle Calcium signalling
6 P38 MAPK signalling Apoptosis
7 Wnt/B-catenin signalling Leukocyte transendothelium migration
8 Glutamate receptor signalling VEGF signalling
9 Integrin signalling Cytokine-cytokine receptor interaction
10 VEGF signalling Neuroactive ligand-receptor interaction
11 IL-6 signalling Wnt signalling
12 Death receptor signalling B cell receptor signalling
13 SAPK/JNK signalling T cell receptor signalling
14 T-cell receptor signalling Focal adhesion
14 pathways derived from the Ingenuity Pathways Analysis
Library (Table 2). The study by Bowen et al. investigated
gene expression and pathway modulation in the gastroin-
testinal tract of rats following irinotecan treatment [3]. They
analysed their gene list using web tool, Pathway Miner,
whichsearchesgenesbasedontheirassociationswithcellular
and regulatory pathways and performs a statistical test
to rank the most signiﬁcant pathways [42]. They found
over 20 pathways from the KEGG database involved in
tissue injury following cytotoxic treatment (Table 2). In both
studies, Fisher’s exact test was applied to the data set to
determine the most signiﬁcant pathways associated with
toxicity. Metabolic pathways were also highly represented in
pathway lists and included nitrogen metabolism, oxidative
phosphorylation, purine metabolism, prostaglandin and
leukotriene metabolism, and glutathione metabolism but
were not investigated further. Gene association networks are
an informative method for analysing pathway relationships
among genes that are coregulated and for analysing up or
down-regulated pathways that contain many participating
genes [42].
These papers are the ﬁrst to use a bioinformatics
approach to deﬁne the pathways altered by anticancer treat-
ment during alimentary mucositis development. Despite
the use of diﬀerent databases in the two studies, there is
considerable overlap within the prioritised pathways named.
The diﬀerence between sampling methods (peripheral blood
verses gastrointestinal whole tissue) makes the results even
more interesting, as it shows that local tissue damage is also
representedsystemically.Thishasimportantimplicationsfor
futureresearch.Itisalsovitalthatfuturestudiesdirecteﬀorts
towards determining which signalling pathways are true
drivers of damage and which are passengers, altered without
causing a functional change at the tissue level. What is more,
the kinetics of pathway activation needs to be determined to
elucidate which are altered early as damage initiators, which
are upregulated as a consequence of damage, and which of
those are crucial to healing. Each represents a separate target
for intervention.
7. FittingTreatments withPathways
There are a growing number of new antimucotoxic agents
currently being clinically tested. Mostly these agents target
at least one or a few pathways identiﬁed as associated
with mucosal injury. However, recent research indicates
that only the agents that modulate multiple pathways will
be truly eﬀective at inhibiting damage. A recent Cochrane
Library review of interventions for preventing oral mucositis
found that of the 33 interventions studied twelve showed
some evidence of a beneﬁt. Of these, two pharmaceutical
agents appear particularly promising, namely, Amifostine
and Benzydamine [43]. These agents have also been included
in the Updated Clinical Practice Guidelines for the Preven-
tion and Treatment of Mucositis [44]. Amifostine is a free
radical scavenger which exerts its eﬀects by reducing direct
DNA damage and reducing upregulation of inﬂammatory
pathways [45]. It has recently been recommended for use in
prevention of radiation-induced proctitis, however it has yet
to be recommended for mucositis [44, 46]. Benzydamine is
recommended for the prevention of mucositis in radiation
patients. It has anti-inﬂammatory, analgesic, anaesthetic and
antimicrobial eﬀects, although its primary mode of action
is thought to be through inhibition of proinﬂammatory
cytokines [14]. Mucositis is essentially an inﬂammatory
condition [47, 48], and the results of the microarray
studies conﬁrm this paradigm by identifying multiple sig-
nalling pathways involved in inﬂammation. These include
NFkB signalling, complement and coagulation cascades,
toll-like receptor signalling, MAPK signalling, cytokine-
cytokine receptor interaction, as well as others shown in
the table above. It seems that these two agents have the
potential to signiﬁcantly ameliorate mucosal injury through
modulating a large number of regulatory pathways. Still,
Palifermin (recombinant human KGF-1) remains the only
agent currently approved by the FDA for the prevention and
treatment of mucositis [49]. It is biologically pleiotropic.
Its primary mode of action was initially thought to rely
on accelerating healing by its role as an epithelial mitogenJournal of Oncology 5
enhancing proliferation, migration, and diﬀerentiation of
mucosal epithelium. However, Palifermin has also been
shown to exhibit protective functions outside of its general
expectedrole,includinginhibitionofepithelialcellapoptosis
and DNA damage, upregulation of detoxifying enzymes,
and downregulation of proinﬂammatory cytokines [50]. It is
likely that Palifermin does this through some of the pathways
discussed. In addition to these drugs, pathway knowledge
could be broadly applied to the development and discovery
of new agents eﬀective in preventing mucosal injury.
8. FutureDirections for Research
One of the major challenges in deﬁning the most appro-
priate molecular targets for mucositis intervention is the
highly complex and interactive nature of its pathobiology.
It seems likely that the main approach to elucidating the
polygenic determinants of treatment will be genomics, in
particular applying the use of anonymous single nucleotide
polymorphism (SNP) maps to perform a genome-wide
search for SNPs associated with treatment eﬀects [51, 52].
This is opposed to the more traditional technique of singly
investigating candidate genes based on existing knowledge
of a drug’s mechanism of action and the known pathways
of metabolism and deposition [51, 52]. This “omic” direc-
tion, coupled with powerful bioinformatics, should greatly
advance our ability to unravel the complex network of
mucosal response to treatment in the near future.
Since it is assumed that the body has only a limited
number of possible responses to injury [46], lessons can also
be learnt from other inﬂammatory conditions. Recurrent
aphthous stomatitis (RAS) is an inﬂammatory disease of
the oral mucosa that is characterised by an aberrant cell-
mediated immune response following external stimuli. The
main feature is ulcer formation precipitated by clinical or
subclinical trauma [53]. The speciﬁc immune defect has yet
to be identiﬁed and the pathogenesis is unknown. However,
a study showed that there are elevated resting levels of
proinﬂammatory cytokines, particularly TNF, within non-
lesional mucosa of patients with RAS compared to normal
controls and lower levels of the anti-inﬂammatory cytokine,
interleukin-10, in RAS patients following trauma. Further-
more, RAS patients all develop ulcers at mucosal trauma
sites, while normal patients show minimal inﬂammation
at the same site [53]. The proposed mechanisms for this
includeenhancedT-cellactivationtogetherwithanincreased
sensitivity of keratinocytes to locally derived cytokines. It
was proposed to be driven by TNF, while an absence of
anti-inﬂammatory interleukin 10 (IL-10) may mediate the
enhancedandprolongedinjuryresponse[53].Morerecently,
a study investigating functional gene polymorphisms in
people with RAS showed a marked increase in the IL-1β
and TNF heterozygous genotypes in ulcer suﬀerers [54].
This indicates a genetic predisposition to ulcer formation
followingmucosalinjury,andduetotheoverlappingfeatures
with regimen-related mucosal injury, the implications are
that polymorphisms in inﬂammatory cascades will also be
useful in predicting mucositis risk.
Finally, a critical point that should be addressed before
any pathway-targeted treatment can be developed is the
need to deﬁne diﬀerences in modulation of pathways in
normal tissue that result in toxicity versus the desired eﬀect
on tumour tissue. We must be careful not to interrupt the
intended purpose of chemotherapy, and therefore consider-
ation needs to be given to designing drugs that are either
speciﬁcally targeted to the mucosal surface or that exploit
features of the normal cell for drug uptake.
9. Conclusions
Alimentary mucositis research has entered the “omic” era.
With this has come a new depth of understanding of the
molecular and cellular interactions associated with devel-
opment of mucosal injury in response to cancer treatment.
One of the most exciting outcomes of recent research
has been the characterisation and prioritising of pathways
implicated in mucositis pathobiology. In the future, this
piece of information will help to rationally design improved
drugs and provide early identiﬁcation of patients at risk of
developing severe mucositis.
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